BJL
HUMA icon

Brighton Jones LLC’s Humacyte HUMA Stock Holding History

Brighton Jones LLC’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.9K Buy
35,726
+13,239
+59% +$12.3K ﹤0.01% 1390
2026
Q1 		$13.6K Buy
+22,487
New +$23.4K ﹤0.01% 1194

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
LWM
LJI Wealth Management Indianapolis, Indiana $714M AUM 21.51% 1-Year Est. Return
UAS
United Asset Strategies Garden City, New York $1.41B AUM 27.73% 1-Year Est. Return

Brighton Jones LLC's HUMA Position: Q2 2026 in Review

Brighton Jones LLC increased its Humacyte (HUMA) stake by 59% in Q2 2026, buying an estimated $12.3K and bringing the position to 35,726 shares worth $27.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1390.

Brighton Jones LLC first reported a position in HUMA in Q1 2026 and has held it in 2 quarters since. 82 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Brighton Jones LLC held 35,726 shares of Humacyte worth $27.9K as of Q2 2026.
  • Brighton Jones LLC bought 13,239 Humacyte shares in Q2 2026, an estimated $12.3K.
  • Humacyte made up ﹤0.01% of Brighton Jones LLC's portfolio in Q2 2026, its #1390 holding.
  • Brighton Jones LLC first reported a position in Humacyte in Q1 2026 and has held it in 2 quarters since.
  • 82 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Brighton Jones LLC's 13F filing for Q2 2026, filed 11 Aug 2026.